[Form 4] BRINKS CO Insider Trading Activity

Brink's (BCO) announced the UK's Competition and Markets Authority accepted its proposed remedy for the acquisition of NCR Atleos (NATL). The company has been cooperating with the regulator to address concerns.

Brink's (BCO) received UK CMA acceptance in principle for its proposed divestiture of NoteMachine/TestLink UK, addressing concerns over its planned NCR Atleos acquisition. The divestiture aims to avoid a Phase 2 referral and is not expected to impact the $200M annual cost synergies from the NCR Atleos deal, which remains on track to close in early Q1 2027, according to the company.

BRINKS CO (BCO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 P R E S S R E L E A S E Contact: Investor Relations 804.289.9709 BRINK’S CORPORATE The Brink’s Company 1801 Bayberry Court Richmond, VA 23226-8100 USA BRINK'S RECEIVES CMA ACCEPTANCE IN PRINCIPLE OF PROPOSED REMEDY RELATING TO PENDING ACQUISITION OF NCR ATLEOS Divest

Brink's (BCO) received UK approval in principle for its proposed remedy in the NCR Atleos (NATL) acquisition, involving the divestiture of NoteMachine/TestLink UK. The sale process is ongoing with multiple buyers engaged, and the deal is expected to close in Q1 2027. The remedy does not affect the expected $200 million in annual cost synergies.

Brink’s (NYSE:BCO) received UK approval in principle for its proposed remedy in the NCR Atleos (NYSE:NATL) acquisition. The company will divest NoteMachine/TestLink UK to address competition concerns. The sale process is ongoing, and the acquisition is expected to close in early Q1 2027. Brink’s CEO stated the divestiture does not impact expected $200M annual cost synergies.

Brink's (BCO) announced the UK's CMA accepted its proposed remedy for the acquisition of NCR Atleos (NATL), involving the divestiture of NoteMachine/TestLink UK. The deal is on track to close in early Q1 2027, with $200M in expected annual cost synergies. Brink's is engaging with prospective buyers for the divestiture.